A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor,as a Single Agent and in Combination with Pembrolizumab inSubjects with Advanced Solid Tumors

Protocol: 
AAAR5080
Phase: 
I

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor,as a Single Agent and in Combination with Pembrolizumab inSubjects with Advanced Solid Tumors

This study is for patients with tumors that cannot be removed (unresectable)
or has spread (metastasized) to a different part of the body. The main
purpose of the study is to determine at what dose the study drug is safe and
tolerated. The study drug is called ASP8374. The study also wants to see how
ASP3874 is processed in the blood. When the safe dose is identified, it will
be used to learn if the study treatment causes tumors to shrink in patients.

Are you Eligible? (Inclusion Criteria)

1. Have tumor(s) that cannot be removed (unresectable) or has spread
(metastasized) to a different part of the body.

2. Participants must be in good physical shape. This means that participants
must be able to walk, care for themselves, and do light physical activities
such as light housework or office work.

3. This study is for participants age 18 or older

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States